Top

Molecular Cancer

Published in:

Open Access 01-12-2016 | Research

ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells

Authors: Reshma Thamkachy, Rohith Kumar, K. N. Rajasekharan, Suparna Sengupta

Published in: Molecular Cancer | Issue 1/2016

Abstract

Background

p53 is a tumour suppressor protein that plays a key role in many steps of apoptosis, and malfunctioning of this transcription factor leads to tumorigenesis. Prognosis of many tumours also depends upon the p53 status. Most of the clinically used anticancer compounds activate p53 dependent pathway of apoptosis and hence require p53 for their mechanism of action. Further, Ras/Raf/MEK/ERK axis is an important signaling pathway activated in many cancers. Dependence of diaminothiazoles, compounds that have gained importance recently due to their anticancer and anti angiogenic activities, were tested in cancer models with varying p53 or Ras/Raf mutational status.

Methods

In this study we have used p53 mutated and knock out colon cancer cells and xenograft tumours to study the role of p53 in apoptosis mediated by diaminothiazoles. Colon cancer cell lines with varying mutational status for Ras or Raf were also used. We have also examined the toxicity and in vivo efficacy of a lead diaminothiazole 4-Amino-5-benzoyl-2-(4-methoxy phenylamino)thiazole (DAT1) in colon cancer xenografts.

Results

We have found that DAT1 is active in both in vitro and in vivo models with nonfunctional p53. Earlier studies have shown that extrinsic pathway plays major role in DAT1 mediated apoptosis. In this study, we have found that DAT1 is causing p53 independent upregulation of the death receptor 5 by activating the Ras/Raf/MEK/ERK signaling pathway both in wild type and p53 suppressed colon cancer cells. These findings are also confirmed by the in vivo results. Further, DAT1 is more efficient to induce apoptosis in colon cancer cells with mutated Ras or Raf.

Conclusions

Minimal toxicity in both acute and subacute studies along with the in vitro and in vivo efficacy of DAT1 in cancers with both wild type and nonfunctional p53 place it as a highly beneficial candidate for cancer chemotherapy. Besides, efficiency in cancer cells with mutations in the Ras oncoprotein or its downstream kinase Raf raise interest in diaminothiazole class of compounds for further follow-up.

Available only for authorised users

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10. doi:10.1038/35042675.CrossRefPubMed

Harris CC. Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88(20):1442–55.CrossRefPubMed

Mroz EA, Rocco JW. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer. J Clin Oncol. 2010;28(5):715–7. doi:10.1200/JCO.2009.26.3475.CrossRefPubMed

Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7(10):2984–97.PubMed

Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–8.CrossRefPubMed

Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–56. doi:10.1038/nrc883.CrossRefPubMed

Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002;111(3):331–42. doi:S009286740201036X.CrossRefPubMed

Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 2000;14(6):704–18.PubMedPubMedCentral

Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449–56.CrossRefPubMed

10.

Wu GS, Burns TF, McDonald 3rd ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17(2):141–3. doi:10.1038/ng1097-141.CrossRefPubMed

11.

Thornborrow EC, Patel S, Mastropietro AE, Schwartzfarb EM, Manfredi JJ. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. Oncogene. 2002;21(7):990–9. doi:10.1038/sj.onc.1205069.CrossRefPubMed

12.

Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7(3):683–94.CrossRefPubMed

13.

Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053–8.CrossRefPubMed

14.

Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001;3(6):552–8. doi:10.1038/3507852735078527.CrossRefPubMed

15.

Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene. 2001;20(26):3449–55. doi:10.1038/sj.onc.1204446.CrossRefPubMed

16.

Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001;61(18):6660–4.PubMed

17.

Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 2004;18(24):3041–54. doi:10.1101/gad.1221004.CrossRefPubMedPubMedCentral

18.

Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12(9):440–50. doi:10.1016/j.molmed.2006.07.007.CrossRefPubMed

19.

Afshar G, Jelluma N, Yang X, Basila D, Arvold ND, Karlsson A, et al. Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res. 2006;66(8):4223–32. doi:10.1158/0008-5472.CAN-05-1283.CrossRefPubMed

20.

Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006;314(5797):294–7. doi:10.1126/science.1130512.CrossRefPubMed

21.

Yount GL, Afshar G, Ries S, Korn M, Shalev N, Basila D, et al. Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene. 2001;20(22):2826–35. doi:10.1038/sj.onc.1204393.CrossRefPubMed

22.

Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116(4):527–40.CrossRefPubMed

23.

Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593–602.CrossRefPubMed

24.

Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature. 1995;376(6535):88–91. doi:10.1038/376088a0.CrossRefPubMed

25.

Romagnoli R, Baraldi PG, Carrion MD, Cruz-Lopez O, Cara CL, Basso G, et al. 2-Arylamino-4-amino-5-aroylthiazoles. “One-pot” synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization. J Med Chem. 2009;52(17):5551–5. doi:10.1021/jm9001692.CrossRefPubMedPubMedCentral

26.

Sengupta S, Smitha SL, Thomas NE, Santhoshkumar TR, Devi SK, Sreejalekshmi KG, et al. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system. Br J Pharmacol. 2005;145(8):1076–83. doi:10.1038/sj.bjp.0706276.CrossRefPubMedPubMedCentral

27.

Thomas NE, Thamkachy R, Sivakumar KC, Sreedevi KJ, Louis XL, Thomas SA, et al. Reversible action of diaminothiazoles in cancer cells is implicated by the induction of a fast conformational change of tubulin and suppression of microtubule dynamics. Mol Cancer Ther. 2014;13(1):179–89. doi:10.1158/1535-7163.MCT-13-0479.CrossRefPubMed

28.

Vasudevan S, Thomas SA, Sivakumar KC, Komalam RJ, Sreerekha KV, Rajasekharan KN, et al. Diaminothiazoles evade multidrug resistance in cancer cells and xenograft tumour models and develop transient specific resistance: understanding the basis of broad-spectrum versus specific resistance. Carcinogenesis. 2015;36(8):883–93. doi:10.1093/carcin/bgv072bgv072.CrossRefPubMed

29.

Thomas SA, Thamkachy R, Ashokan B, Komalam RJ, Sreerekha KV, Bharathan A, et al. Diaminothiazoles inhibit angiogenesis efficiently by suppressing Akt phosphorylation. J Pharmacol Exp Ther. 2012;341(3):718–24. doi:10.1124/jpet.112.192559.CrossRefPubMed

30.

Thomas SA, Vasudevan S, Thamkachy R, Lekshmi SU, Santhoshkumar TR, Rajasekharan KN, et al. Upregulation of DR5 receptor by the diaminothiazole DAT1 [4-amino-5-benzoyl-2-(4-methoxy phenyl amino) thiazole] triggers an independent extrinsic pathway of apoptosis in colon cancer cells with compromised pro and antiapoptotic proteins. Apoptosis. 2013;18(6):713–26. doi:10.1007/s10495-013-0826-6.CrossRefPubMed

31.

MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;272(41):25417–20.CrossRefPubMed

32.

Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818–21.CrossRefPubMed

33.

Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277(5327):815–8.CrossRefPubMed

34.

Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res. 2001;262(2):154–69. doi:10.1006/excr.2000.5073S0014-4827(00)95073-0.CrossRefPubMed

35.

Prasad S, Yadav VR, Kannappan R, Aggarwal BB. Ursolic acid, a Pentacyclin Triterpene, Potentiates TRAIL-induced Apoptosis through p53-independent Up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J Biol Chem. 2010;286(7):5546–57. doi:10.1074/jbc.M110.183699.CrossRefPubMedPubMedCentral

36.

Seol D-W. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun. 2011;416(1–2):222–5. doi:10.1016/j.bbrc.2011.11.053.CrossRefPubMed

37.

Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumour necrosis factor alpha. Cancer Res. 1998;58(8):1593–8.PubMed

38.

Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87(19):7555–9.CrossRefPubMedPubMedCentral

39.

Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001;20(2):147–55. doi:10.1038/sj.onc.1204062.CrossRefPubMed

40.

Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104(3):263–9. doi:10.1172/JCI6863.CrossRefPubMedPubMedCentral

41.

Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem. 2004;279(9):7598–605. doi:10.1074/jbc.M311732200.CrossRefPubMed

42.

Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene. 1998;16(12):1617–24. doi:10.1038/sj.onc.1201658.CrossRefPubMed

43.

Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 1997;7(6):821–30.CrossRefPubMed

44.

Strniskova M, Barancik M, Ravingerova T. Mitogen-activated protein kinases and their role in regulation of cellular processes. Gen Physiol Biophys. 2002;21(3):231–55.PubMed

45.

Kyosseva SV. Mitogen-activated protein kinase signaling. Int Rev Neurobiol. 2004;59:201–20. doi:10.1016/S0074-7742(04)59008-6.CrossRefPubMed

46.

Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol. 2005;38(1):47–62. doi:10.1016/j.yjmcc.2004.11.004.CrossRefPubMed

47.

Rennefahrt U, Janakiraman M, Ollinger R, Troppmair J. Stress kinase signaling in cancer: fact or fiction? Cancer Lett. 2005;217(1):1–9. doi:10.1016/j.canlet.2004.08.003.CrossRefPubMed

48.

Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem. 2005;280(24):22856–67. doi:10.1074/jbc.M412483200.CrossRefPubMed

49.

Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumour necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004;64(11):3922–7. doi:10.1158/0008-5472.CAN-03-221964/11/3922.CrossRefPubMed

50.

Shenoy K, Wu Y, Pervaiz S. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. Cancer Res. 2009;69(5):1941–50. doi:10.1158/0008-5472.CAN-08-1996.CrossRefPubMed

51.

Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: ‘it ain’t over ‘til it’s over’. Trends Cell Biol. 2000;10(4):147–54.CrossRefPubMed

52.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. doi:10.1038/nature00766.CrossRefPubMed

53.

Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24(4):703–10.CrossRefPubMed

54.

Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2, e71. doi:10.1038/oncsis.2013.35.CrossRefPubMedPubMedCentral

55.

Magudia K, Lahoz A, Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol. 2012;198(2):185–94. doi:10.1083/jcb.201202108.CrossRefPubMedPubMedCentral

56.

De Bosscher K, Hill CS, Nicolas FJ. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J. 2004;379(Pt 1):209–16. doi:10.1042/BJ20031886.CrossRefPubMedPubMedCentral

57.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumours to cetuximab. Oncogene. 2011;30(5):561–74. doi:10.1038/onc.2010.430.CrossRefPubMedPubMedCentral

58.

Cagnol S, Chambard J-C. ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J. 2010;277(1):2–21. doi:10.1111/j.1742-4658.2009.07366.x.CrossRefPubMed

59.

Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–42. doi:10.1038/nrd4281.CrossRefPubMed

60.

Lee M, Young Kim S, Kim J, Kim HS, Kim SM, Kim EJ. Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death. Cancer Biol Ther. 2013;14(11):1007–15. doi:10.4161/cbt.2604426044.CrossRefPubMedPubMedCentral

61.

Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3(14):1787–808. doi:10.4155/fmc.11.121.CrossRefPubMedPubMedCentral

62.

Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–67. doi:10.1038/nrc3760.CrossRefPubMedPubMedCentral

63.

Sreejalekshmi KGDS. Rajasekharan KN An efficient protocol for solid phase aminothiazole synthesis. Tetrahedron Lett. 2006;47:6179–82.CrossRef

64.

Smakman N, Van Den Wollenberg DJ, Elias SG, Sasazuki T, Shirasawa S, Hoeben RC, et al. KRAS(D13) Promotes apoptosis of human colorectal tumour cells by ReovirusT3D and oxaliplatin but not by tumour necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2006;66(10):5403–8. doi:10.1158/0008-5472.CAN-05-4108.CrossRefPubMed

Title: ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells
Authors: Reshma Thamkachy
Rohith Kumar
K. N. Rajasekharan
Suparna Sengupta
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-016-0505-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α

Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma

Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia’

Rac1-mediated cytoskeleton rearrangements induced by intersectin-1s deficiency promotes lung cancer cell proliferation, migration and metastasis

miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis

Long noncoding RNAs in cancer: mechanisms of action and technological advancements

Keynote webinar | Spotlight on antibody–drug conjugates in cancer